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One of the aims of this thesis was to investigate if the binding of [18F]-MPPF 
to the 5-HT1A receptor is sensitive to changes in endogenous 5-HT levels. 
The [18F]-MPPF study in humans has shown that the binding of this ligand 
was not affected by small changes in 5-HT levels, as induced by tryptophan 
depletion and infusion. In rats, the binding of [18F]-MPPF was decreased 
after fenfluramine-induced increases in 5-HT levels, whereas the 
combination of citalopram with ketanserin did not induce significant changes 
in ligand binding. Microdialysis studies showed that these treatments 
resulted in 30-fold and 10-fold increases in extracellular 5-HT levels 
respectively. The study in monkeys revealed that fenfluramine-induced 
increases in 5-HT did not affect [18F]-MPPF binding under equilibrium 
conditions, although the increases were comparable to those in the rat 
study. In contrast, an equilibrium study with the D2 ligand [11C]-raclopride 
showed that the binding of this ligand was affected by a relatively low dose 
of the DA reuptake blocker methylphenidate. Microdialysis studies indicate 
that the increases in DA levels after this dose were less than 6-fold (Huff 
and Davies 2002). Moreover, the DA-induced changes in [11C]-raclopride 
binding correlated with subjective experiences. Significant correlations were 
found between the methylphenidate-induced change in euphoria and 
percent change in binding potential (ΔBP) in the dorsal striatum and 
between baseline anxiety and ΔBP in the dorsal and middle striatum. We 
also found a significant negative correlation between baseline BP in the 
dorsal striatum and change in euphoria. The [15O]-H2O PET study showed 
that methylphenidate induced euphoria-related rCBF increases in the AC, a 
region that is involved in DA-associated disturbances in emotion regulation 
and motivated behavior. When interpreting the results of these studies it is 
important to consider the following issues. 
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Measurement of changes in neurotransmitter 
release 
The results of the serotonergic competition studies showed that [18F]-MPPF 
binding was not consistently affected after large increases in 5-HT levels, 
despite the fact that in vitro studies have shown that 5-HT is able to 
compete with [18F]-MPPF binding to the 5-HT1A receptor (Watson et al. 
2000). In contrast, [11C]-raclopride binding was significantly affected after 
relatively small increases in DA levels. 
Extent and timing of changes in neurotransmitter release 
The results of the [18F]-MPPF studies indicate that only very large increases 
in 5-HT concentration may possibly affect ligand binding at the 5-HT1A 
receptor. Especially in human subjects, safety issues preclude the use of 
such challenges. With respect to the timing of the challenge, it has been 
shown that in bolus studies the extent of the change in ligand binding may 
theoretically be affected by the timing of the challenge. Optimal changes in 
tissue concentration are predicted if the concentration of the competitor 
follows the peak in free ligand concentration (Endres and Carson 1998; 
Morris 1995; Yoder et al. 2004). This may possibly have affected the 
changes in ligand uptake in our rat studies, where [18F]-MPPF was 
administered as a bolus injection. It would also imply that if equilibrium is not 
achieved and ligand binding is still increasing, net binding will be little 
affected by increases in neurotransmitter (Gatley et al. 2000). However, in 
equilibrium situations, as used in chapter 4 and 5, the changes in ligand 
binding are insensitive to timing of the challenge. 
Internalization 
A difference between the serotonergic and dopaminergic system concerns 
the internalization of receptors. It has been shown that, in contrast to 
(postsynaptic) 5-HT1A receptors, D2 receptors are internalized after agonist 
stimulation (Riad et al. 2004; Sun et al. 2003). As mentioned in the 
introduction, a few studies reported cholinergic, adrenergic and opioid 
ligands to be sensitive to competition with the endogenous neurotransmitter. 
It is noteworthy that the muscarinic-cholinergic, alpha2-adrenergic and mu-
opioid receptors are also found to be internalized after agonist stimulation 
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(Keith et al. 1998; Maloteaux and Hermans 1994; Olli-Lahdesmaki et al. 
1999). However, the internalization of agonist-induced receptors may 
explain the duration of reduced ligand binding but not the initial decrease. 
Changes in blood flow 
The drugs that are used in pharmacological challenge studies may induce 
changes in blood flow. Since PET ligands are administered via the blood 
circulation their distribution may theoretically be affected by drug-induced 
changes in blood flow. This could lead to erroneous measurements of BP 
changes. With computer simulations, using the kinetic rate constants of the 
ligand, possible effects of changes in blood flow on ligand binding can be 
predicted. For example, in a simulation study with [18F]-fallypride, Slifstein et 
al. (2004) calculated that changes in blood flow will have only small effects 
on the binding of this ligand. In case of good dynamic data, kinetic models 
which explicitly incorporate blood flow may also provide information on and 
correct for effects of blood flow changes during the experiment (Logan et al. 
1994). Currently, it is not known to what extent the binding of [18F]-MPPF is 
affected by changes in blood flow. However, under equilibrium conditions, 
as used in chapter 4 and 5, there is no net radiotracer transfer across the 
blood-brain barrier and possible effects of drug-induced changes in blood 
flow can therefore be excluded. 
Ligand characteristics 
Under equilibrium conditions and using tracer doses, changes in specific 
binding are not dependent on the affinity of the ligand (Abi-Dargham et al, 
1999; Laruelle 2000). However, simulation studies have shown that the 
kinetic properties of the ligand play a role when total uptake of the ligand is 
studied (Endres and Carson 1998). Based on the calculations in the study of 
Endres and Carson, it can be assumed that the relatively low BP of the 
ligands in our studies should enable optimal detection of drug-induced 
signal changes in case of bolus with constant infusion. 
Receptor compartments 
As mentioned before, the 5-HT1A and D2 receptors are located both 
extrasynaptically and intrasynaptically. It is possible that the 
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pharmacological challenges differentially affect neurotransmitter levels in 
these two receptor compartments, depending on their mechanism of action. 
The SERT is mainly located extrasynaptically (Zhou et al. 1998) and the 
striatal DAT both intrasynaptically and extrasynaptically (Sesack et al. 
1998). Blockade of these transporters thus results in either extrasynaptic or 
both extra- and intrasynaptic increases in neurotransmitter levels, 
respectively. A drug-induced stimulation of the release of the transmitter 
may involve exocytotic (synaptic) and transporter mediated (extrasynaptic) 
processes, thereby leading to compartment specific changes in 
neurotransmitter levels. Fenfluramine increases 5-HT levels via both release 
mechanisms, in addition to blockade of its reuptake (Crespi et al. 1997). 
Methylphenidate is shown to block the reuptake of DA through binding to 
the DA transporter. Based on the these data, it can be assumed that both 
fenfluramine and methylphenidate lead to neurotransmitter changes in the 
intrasynaptic and extrasynaptic compartments. 
Effects of anesthesia 
Previous studies have shown that ligand binding may be affected by the use 
of different anesthetics. The mechanism of these effects is not completely 
understood but may be related to changes in cerebral blood flow or receptor 
affinity (Ginovart et al. 2002; Harada et al. 2004; Hassoun et al. 2003; 
Momosaki et al. 2004; Seeman and Kapur 2003; Tsukada et al. 2002). 
Anesthetics may also affect serotonergic transmission (Dringenberg and 
Vanderwolf 1995; Dringenberg et al. 1995; Mokler et al. 1998) and reduce 
agonist binding to the 5-HT1A receptor (Kalipatnapu and Chattopadhyay 
2004). Because of the possible effects of anesthetics on 5-HT1A binding, we 
have chosen to perform our rat and monkey studies in conscious animals. 
However, previous studies were often performed in anesthetized animals 
(Hume et al. 2001; Maeda et al. 2001; Zimmer et al. 2002). The effects of 
anesthesia may possibly explain some of the discrepancies in results from 
5-HT1A competition studies, such as the large changes in [18F]-MPPF 




Affinity state of receptors 
The relative insensitivity of serotonergic ligands to changes in 5-HT levels 
may be explained by the large proportion of 5-HT1A receptors in the low 
affinity state, as suggested in the first three chapters of this thesis. In 
contrast, the proportion of D2 receptors in the high affinity state is much 
larger (Cumming et al. 2002; Narendran et al. 2004). As mentioned before, 
muscarinic-cholinergic, alpha2-adrenergic and opioid ligands were found to 
be sensitive to competition with the endogenous neurotransmitter (Carson 
et al. 1998; Nishiyama et al. 2001; Skaddan et al. 2002; Tyacke et al. 2005). 
Previous studies have reported that a large proportion of alpha2 and opioid 
receptors is in the high affinity state (Bunzow et al. 1995; Ribas et al. 2001). 
Most cholinergic receptors are located extrasynaptically, and it can therefore 
be assumed that these receptors are also configured in the high affinity 
state (Descarries et al. 1997; Vizi 2000). These data signify the importance 
of the affinity state of receptors in neurotransmitter competition studies. 
Additionally, it should be noted that the proportion of receptors in the high 
affinity state may depend on the species or the use of anesthetics. 
Baseline neurotransmitter concentration 
The baseline concentration of the neurotransmitter may also play a role in 
the sensitivity of the binding of the ligand to competition. If baseline levels 
are high (closer to the KD of the receptor), ligand binding is more easily 
affected by increases in neurotransmitter concentration. If the concentration 
of the neurotransmitter is high enough, this may even result in competition 
at the receptors in the low affinity state. In this respect it is important to 
realize that the baseline level of 5-HT depends on the activity state of the 
animal: high during active waking and low during sleep. All our experiments 
were performed during daytime, which is the resting period of rats and 
waking period of rhesus monkeys. Microdialysis experiments have shown, 
however, that the baseline concentration of 5-HT was comparable in our 
experiments in rats and monkeys (around 0.9 nM). Compared to the 
relatively low baseline level of 5-HT, the baseline concentration of DA is 
much higher (more than 10-fold) (Westerink and de Vries 1991). This may 
have contributed to the fact that, in contrast to the binding of [18F]-MPPF, 





The results of our rCBF study comply with the current knowledge of 
dopamine-induced changes in brain activation. As mentioned before, the 
effects of psychostimulants depend on the nature of the pharmacological 
challenge (Pontieri et al. 1990), the dose (Porrino and Lucignani 1987; 
Vollenweider et al. 1998), the use of anesthesia (Cash et al. 2003), the 
route of administration (Porrino 1993), immobilization (London et al. 1990), 
the baseline state of the subject (Volkow et al. 1997, 1998), the timing of the 
measurement (Porrino 1993; Stein and Fuller 1993), or whether changes in 
relative or absolute rCBF or metabolism are measured. 
 
Interpretation of the results from activation studies is not always 
straightforward. For instance, neurotransmitter-induced effects on blood flow 
via direct interaction with receptors on blood vessels can not be excluded. In 
our study we corrected for global changes, and therefore the observed 
changes in rCBF are largely independent of global effects on blood flow. A 
local cerebrovascular effect can not be controlled for however, and can 
therefore not be excluded. Choi et al. (2003) studied the possible vascular 
effects of DA using fMRI and found that the hemodynamic change induced 
by dopaminergic ligands may be mediated through D1/D5 receptors on the 
vasculature. However, Schwarz et al. (2004) has shown that direct 
vasoactivity of DA is unlikely to be the dominant mechanism underlying the 
rCBF response, since changes in DA did not reflect the temporal profile of 
the rCBF response in their study. In previous studies, the authors have 
speculated on the origin of the regional changes in brain activation after 
drug-induced modulation of neurotransmitter release. Sometimes a 
distinction is made between subjective and neurotransmitter-related rCBF 
changes, in order to explain the results. In other studies, primary effects of 
the neurotransmitter are distinguished from secondary effects (Gamma et 
al. 2000; Grasby et al. 1992, 1993; Mann et al. 1996; Smith et al. 2002). 
However, since changes in brain activation are primarily due to changes in 
glutamatergic signaling (Attwell and Laughlin 2001), all findings must be 
interpreted in terms of anatomical circuits where the challenge induces 





The subjects that were included in the studies in this thesis were all healthy 
controls. It is generally assumed that the variability within a group of normal 
volunteers is small. Evidence exists, however, that brain function may differ 
significantly between subjects. Previous studies have reported individual 
differences in dopaminergic or serotonergic function, such as receptor 
density or neurotransmitter release, which are related to personality, gender 
or aging. As indicated in chapter 5, the outcome of neurobiological 
experiments may partly be explained by these inter-individual differences in 
subject characteristics. In that study, the baseline level of anxiety correlated 
with the extent of methylphenidate-induced increases in DA concentration. 
Personality 
Several studies have found correlations between neurotransmitter function 
and personality traits. With respect to the dopaminergic system, the D2 and 
DAT densities were found to be related to detachment (Breier et al. 1998) 
and dopamine synthesis capacity to anxiety-related traits and irritability 
(Laakso et al. 2003). The extent of dopamine release was shown to be 
related to novelty seeking behavior (Leyton et al. 2002). The serotonergic 
system is also found to be involved in personality traits. The 5-HT1A receptor 
density is reported to be correlated to self-transcendence (Borg et al. 2003), 
anxiety (Tauscher et al. 2001a) and aggression (Parsey et al. 2002), 
although correlations with personality traits were not always found (Rabiner 
et al. 2002). The 5-HT2 receptor density is suggested to play a role in harm 
avoidance behavior (Moresco et al. 2002). In addition, the responsiveness 
of the dopaminergic and serotonergic neurotransmitter systems may be 
related to the individual reaction to stress. (Amat et al. 1998; Bland et al. 
2003; Marsteller et al. 2002; Oswald et al. 2005) and different forms of 
stress may have different effects on neurotransmitter release (Amat et al. 
1998; Bland et al. 2003). Methodological differences between studies could 
therefore affect the study outcome if one condition is more stressful than 
another condition. This may partly explain the different outcome of the 




An association between personality traits and biological parameters is also 
seen in brain activation studies. Youn et al. (2002) found that different 
temperament types correspond to different patterns of baseline brain 
metabolism and Keightley et al. (2003) found personality-related differences 
in rCBF under transient emotional stress. As mentioned in chapter 6, the 
differences in AC activation may also be related to personality type (Canli et 
al. 2001, Johnson et al. 1999; Sugiura et al. 2000).  
Gender 
Dopaminergic or serotonergic function may also be related to the gender of 
the subject. So far, no evidence exists for gender-related differences in D2 
or 5-HT2 receptor density (Adams et al. 2004; Farde et al. 1995), but several 
studies have reported differences in 5-HT1A density (Parsey et al. 2002; 
Meltzer et al. 2001) and serotonin synthesis capacity (Chugani et al. 1998; 
Nishizawa et al. 1997; Okazawa et al. 2000). Gender differences were also 
found in studies that investigated resting state brain metabolism or rCBF 
(Andreason et al. 1994; George et al. 1996; Kawachi et al. 2002) and mood-
related changes in rCBF (George et al. 1996).  
Aging 
The density of the DAT and D2 and 5-HT2 receptors is found to decline with 
age (Adams et al. 2004; Kaasinen et al. 2000; Lavalaye et al. 2000). Effects 
of age on 5-HT1A receptor density were found in some studies but not in all 
(Meltzer et al. 2001; Parsey et al. 2002; Rabiner et al. 2002; Tauscher et al. 
2001b). In the study described in chapter 2, we did not find correlations 
between 5-HT1A receptor binding and age. The effects of age on brain 
metabolism were studied by Kawachi et al. (2002). They reported significant 
correlations between aging and glucose metabolism in several brain 
regions. 
 
In the studies described in chapter 5 and 6, both males and females were 
included of different ages, although all relatively young. Because of the 
relatively small number of subjects we did not correct for these differences 
and some of the variability in our studies may be related to gender or age-
related factors. In addition, in none of our studies, we used personality 
scales to assess differences in character or temperament. Due to the 
voluntary basis of participation in these studies, it is possible that the 
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personality of the included volunteers differed from the average population. 
It can, for instance, be assumed that the percentage of novelty seekers in 
our studies was higher than on average. Studies with a larger number of 
subjects could provide more information on the exact contribution of these 
factors. 
Beyond dopamine and serotonin 
Although drug treatment of psychiatric disorders such as depression and 
schizophrenia has largely focused on the modulation of serotonergic and 
dopaminergic transmission, it is not known if the underlying pathophysiology 
of these disorders is causally related to abnormalities in these systems. 
Current research focuses on interactions between these and other systems 
and evidence exists for the involvement of neurotransmitters such as GABA 
or glutamate. Additionally, an increasing number of studies have implicated 
other factors such as stress, abnormal gene expression, environmental 
effects, disturbed immune function, changes in synaptic function and 
plasticity or intracellular mechanisms in the etiology of psychiatric disorders 
(Bosker et al. 2004; Carlsson et al. 2001; Harrison 1999; Harrison and 
Eastwood 2001; Schiffer et al. 2003; Smith et al. 1997). However, as 
described in this thesis, a large amount of evidence indicates the 
involvement of the dopaminergic and serotonergic systems in (the treatment 
of) psychiatic disorders. 
Conclusions 
Alterations in serotonin levels may theoretically be assessed using ligands 
that are sensitive to changes in the concentration of this neurotransmitter. 
The results of the [18F]-MPPF study in human subjects showed that the 
binding of this ligand is not significantly affected by physiological changes in 
5-HT levels. This finding indicates that this ligand is not suitable for 
detection of disease or drug-related 5-HT changes in human subjects. In a 
bolus study in rats, the binding of [18F]-MPPF was found to be decreased 
after considerable increases in 5-HT levels. However, a bolus with constant 
infusion study in monkeys did not show significant changes in ligand binding 
after comparable increases in 5-HT levels. The reason for this discrepancy 
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is yet unknown, but may be related to methodological factors such as drug-
induced changes in blood flow or differences in the proportion of receptors 
in the high affinity state. In contrast to these serotonergic studies, an 
equilibrium study with the D2 ligand [11C]-raclopride showed significant 
reductions in ligand binding after a relatively low dose of the DA reuptake 
blocker methylphenidate. Two major differences between the serotonergic 
5-HT1A and dopaminergic D2 receptor systems, concern the proportion of 
receptors in the high affinity state and the baseline neurotransmitter 
concentration. Currently, these findings are the most likely explanation for 
the differences in sensitivity between the two systems. The measured 
changes in DA release were also found to be related to subjective effects, 
such as euphoria and baseline anxiety. These results comply with previous 
studies, indicating the feasibility of this design to study dopaminergic 
(dys)function in psychiatric disorders such as depression. The combination 
of methylphenidate with [15O]-H2O PET also showed euphoria-related 
changes in dopaminergic function and thereby offers another useful design 
to study the functional integrity of the dopaminergic system in future studies. 
Future studies 
The insensitivity of 5-HT1A ligands to changes in 5-HT levels may be 
explained by the relatively small proportion of receptors in the high affinity 
state in vivo, as stated earlier. Labeled agonists to the 5-HT1A receptor could 
possibly be used to show effects of 5-HT increases on ligand binding at the 
high affinity receptors. Unfortunately, the first attempts to develop such 
ligands were unsuccessful, despite the high affinity of these ligands for the 
5-HT1A receptor (Pike et al. 2001; Zimmer et al. 2003). Possibly the 
proportion of 5-HT1A receptors in the high affinity state is simply too low to 
enable measurable binding with these ligands. Alternatively, attention could 
be focused on other serotonergic sites, such as the SERT. A study by 
Ginovart et al. (2003) showed that the binding of the SERT ligand [11C]-
DASB was reduced after administration of the MAO inhibitor 
tranylcypromine. With respect to the dopaminergic system, the combination 
of methylphenidate with [11C]-raclopride constant infusion, may be used to 
improve the knowledge on the function of the dopaminergic system in 
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psychiatric disorders. Additionally, this method may provide information on 
the mechanism of action of drugs in development. 
 
Our studies have shown that it may be difficult to find suitable ligands to 
measure changes in neurotransmitter levels. Moreover, due to the lack of 
specific ligands, it has not been possible to study the role of a number of 
receptor subtypes. In these cases, functional studies using [15O]-H2O PET 
or fMRI, possibly in combination with cognitive or emotional tasks, may 
provide information on the effects of psychoactive drug challenges. The 
results of our [15O]-H2O PET study with methylphenidate indicate the 
potential usefulness of such studies in psychiatric research or drug 
development. 
 
Future studies may also provide insight in the involvement of age, gender 
and personality-related factors in the results of neuroimaging studies. In 
addition, it would be interesting to study the contribution of these subject 
related characteristics to the pathogenesis and treatment of psychiatric 
disorders. These studies may also lead to a greater understanding of the 
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